Nobivac L4

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Interrogans серовара лептоспир серогруппы Кашницкого Портланд-вяра (щам Sa-12-000) и L. interrogans серовара Copenhageni серогруппы Icterohaemorrhagiae (щам SK-02-001), l. interrogans серогруппы Аустралис серовара Братислава (щам на Ас-05-073), la kirschneri серогруппы Grippotyphosa серовара Dadas (щам гр-01-005)

Available from:

Intervet International BV

ATC code:

QI07AB01

INN (International Name):

Vaccine to prevent Leptospira infections in dogs

Therapeutic group:

Кучета

Therapeutic area:

Имунологични

Therapeutic indications:

За активна имунизация на кучета срещу:interrogans серовара лептоспир серогруппы Кашницкого Тянитолкая за намаляване на инфекция и экскреция;л. interrogans серогруппы Icterohaemorrhagiae Copenhageni серовара за намаляване на инфекция и экскреция;л. interrogans серогруппы Аустралис серовара Братислава за намаляване на инфекция;л. kirschneri серогрупа Grippotyphosa serovar Bananal / Lianguang за намаляване на инфекцията и отделяне на урина.

Product summary:

Revision: 6

Authorization status:

упълномощен

Authorization date:

2012-07-16

Patient Information leaflet

                                14
B.
ЛИСТОВКА
15
ЛИСТОВКА:
NOBIVAC L4 ИНЖЕКЦИОННА СУСПЕНЗИЯ ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба и
производител, отговорен за
освобождаване на партидата
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Nobivac L4 инжекционна суспензия за кучета
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ЕКСЦИПИЕНТИТЕ
Една доза (1ml) съдържа:
АКТИВНИ СУБСТАНЦИИ
:
Инактивирани
_Leptospira _
щамове:
-
_L.interrogans _
серогрупа Canicola серотип Portland-vere (щам
Ca-12-000)
3550-7100 U
1
-
_L.interrogans_
серогрупа Icterohaemorrhagiae серотип Copenhageni
(щам Ic-02-001)
290-1000 U
1
-
_L.interrogans_
серогрупа Australis серотип Bratislava (щам
As-05-073)
500-1700 U
1
-
_L.kirschneri_
серогрупа Grippotyphosa серотип Dadas (щам
Gr-01-005)
650-1300 U
1
1
Антигенно количество ELISA единици
Безцветна суспензия.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
За активна имунизация на кучета срещу:
-
_L.interrogans_
серогрупа Canicola серотип Canicola за
ограничаване на инфекцията и
уринарната екскреция
-
_L.interrogans _
серогрупа Icterohaemorrhagiae серотип Copenhageni за
ограничаване на
инфекцията и уринарната екскреция
-
_L.interrogans_
серогрупа Australis серотип Bratislava за
ограничаван
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Nobivac L4 инжекционна суспензия за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Една доза (1 ml) съдържа:
АКТИВНИ СУБСТАНЦИИ
:
Инактивирани
_Leptospira _
щамове:
-
_L_
.
_interrogans_
серогрупа Canicola серотип Portland-vere (щам
Ca-12-000)
3550-7100 U
1
-
_L. interrogans_
серогрупа Icterohaemorrhagiae серотип Copenhageni
(щам Ic-02-001)
290-1000 U
1
-
_ L_
.
_interrogans _
серогрупа Australis серотип Bratislava (щам
As-05-073)
500-1700 U
1
-
_L_
.
_ kirschneri _
серогрупа Grippotyphosa серотип Dadas (щам
Gr-01-005)
650-1300 U
1
1
Антигенно количество ELISA единици
ЕКСЦИПИЕНТИ:
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Инжекционна суспензия.
Безцветна суспензия.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
За активна имунизация на кучета срещу:
-
_L.interrogans_
серогрупа Canicola серотип Canicola за
ограничаване на инфекцията и
уринарната екскреция
-
_L.interrogans_
серогрупа Icterohaemorrhagiae серотип Copenhageni за
ограничаване на
инфекцията и уринарната екскреция
-
_ L.interrogans_
серогрупа Australis серотип Bratislava за
ограничаване на инфекцията
-
_L.kirschneri _
серогрупа Grippotyphosa сер
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 11-11-2021
Public Assessment Report Public Assessment Report Spanish 29-01-2013
Patient Information leaflet Patient Information leaflet Czech 11-11-2021
Public Assessment Report Public Assessment Report Czech 29-01-2013
Patient Information leaflet Patient Information leaflet Danish 11-11-2021
Public Assessment Report Public Assessment Report Danish 29-01-2013
Patient Information leaflet Patient Information leaflet German 11-11-2021
Public Assessment Report Public Assessment Report German 29-01-2013
Patient Information leaflet Patient Information leaflet Estonian 11-11-2021
Public Assessment Report Public Assessment Report Estonian 29-01-2013
Patient Information leaflet Patient Information leaflet Greek 11-11-2021
Public Assessment Report Public Assessment Report Greek 29-01-2013
Patient Information leaflet Patient Information leaflet English 11-11-2021
Public Assessment Report Public Assessment Report English 29-01-2013
Patient Information leaflet Patient Information leaflet French 11-11-2021
Public Assessment Report Public Assessment Report French 29-01-2013
Patient Information leaflet Patient Information leaflet Italian 11-11-2021
Public Assessment Report Public Assessment Report Italian 29-01-2013
Patient Information leaflet Patient Information leaflet Latvian 11-11-2021
Public Assessment Report Public Assessment Report Latvian 29-01-2013
Patient Information leaflet Patient Information leaflet Lithuanian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-11-2021
Public Assessment Report Public Assessment Report Lithuanian 29-01-2013
Patient Information leaflet Patient Information leaflet Hungarian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 11-11-2021
Public Assessment Report Public Assessment Report Hungarian 29-01-2013
Patient Information leaflet Patient Information leaflet Maltese 11-11-2021
Public Assessment Report Public Assessment Report Maltese 29-01-2013
Patient Information leaflet Patient Information leaflet Dutch 11-11-2021
Public Assessment Report Public Assessment Report Dutch 29-01-2013
Patient Information leaflet Patient Information leaflet Polish 11-11-2021
Public Assessment Report Public Assessment Report Polish 29-01-2013
Patient Information leaflet Patient Information leaflet Portuguese 11-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 11-11-2021
Public Assessment Report Public Assessment Report Portuguese 29-01-2013
Patient Information leaflet Patient Information leaflet Romanian 11-11-2021
Public Assessment Report Public Assessment Report Romanian 29-01-2013
Patient Information leaflet Patient Information leaflet Slovak 11-11-2021
Public Assessment Report Public Assessment Report Slovak 29-01-2013
Patient Information leaflet Patient Information leaflet Slovenian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 11-11-2021
Public Assessment Report Public Assessment Report Slovenian 29-01-2013
Patient Information leaflet Patient Information leaflet Finnish 11-11-2021
Public Assessment Report Public Assessment Report Finnish 29-01-2013
Patient Information leaflet Patient Information leaflet Swedish 11-11-2021
Public Assessment Report Public Assessment Report Swedish 29-01-2013
Patient Information leaflet Patient Information leaflet Norwegian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 11-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 11-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 11-11-2021
Patient Information leaflet Patient Information leaflet Croatian 11-11-2021

View documents history